Loading...
•
Jun 30, 2023
IRadimed Q2 2023 Earnings Report
IRadimed achieved record revenue for Q2 2023 and raised full year guidance.
Key Takeaways
IRadimed Corporation reported record revenue of $16.1 million for the second quarter of 2023, representing over 25% year-over-year growth. GAAP diluted EPS was $0.33, and non-GAAP diluted EPS was $0.36. The company also announced increased financial guidance for the full year 2023, expecting revenue between $64.5 million and $65.5 million.
Record revenue of $16.1 million reported for Q2 2023
GAAP diluted EPS was $0.33 and non-GAAP diluted EPS was $0.36
Operating income was $5.0 million, a 19% increase year-over-year
Full year 2023 revenue guidance raised to $64.5 million - $65.5 million
Forward Guidance
For the third quarter of 2023, the Company expects to report revenue of $16.1 million to $16.3 million, GAAP diluted earnings per share of $0.33 to $0.35, and non-GAAP diluted earnings per share of $0.36 to $0.38. For the full-year 2023 financial guidance the Company now expects to report revenue of $64.5 million to $65.5 million, GAAP diluted earnings per share of $1.25 to $1.28, and non-GAAP diluted earnings per share of $1.37 to $1.40.
Positive Outlook
- Revenue of $16.1 million to $16.3 million expected
- GAAP diluted earnings per share of $0.33 to $0.35 expected
- Non-GAAP diluted earnings per share of $0.36 to $0.38 expected
- Full year revenue of $64.5 million to $65.5 million expected
- Full year GAAP diluted earnings per share of $1.25 to $1.28 expected
Challenges Ahead
- The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...